Pediatric safety and pharmacokinetic findings supported expanding leniolisib to children aged 4 to 11 years who weigh at least 27 kg, establishing the first FDA-approved treatment for activated...
Canadian researchers assessed whether exposure to wildfire-related fine particulate matter was associated with ED visits for migraine and other headaches.
At the August 2026 Practical Updates in Primary Care Virtual Meeting, Rakesh Jain, MD, MPH, and Laura Melaro, DNP, APRN, FNP-BC, PMHNP-BC, outlined a practical primary care approach to adult...
Intismeran autogene plus pembrolizumab met the primary recurrence-free survival and a key secondary distant metastasis-free survival endpoint in the phase 3 INTerpath-001 trial in patients with completely...
The FDA granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab, hyaluronidase-fihj, and dexamethasone for adults with multiple myeloma previously treated with a proteasome...
In the double-blind EPCAT III RCT, aspirin alone was noninferior to 5 days of rivaroxaban followed by aspirin for preventing symptomatic VTE after total hip or knee arthroplasty, with no clinically relevant...
A retrospective surveillance study of critical care units at a tertiary care hospital found high CAUTI/UTI and CLABSI rates, with CLABSI rates increasing 2.64-fold during the COVID-19 era.
In a multicenter dose de-escalation and expansion study of adults with HIV-related DLBCL, ibrutinib plus R-da-EPOCH showed manageable toxicity and clinical activity, with 3-year event-free and overall...
The FDA approval introduces a nonprescription fixed-dose combination of 2 widely used analgesics for temporary relief of common minor aches and pains in adults and children aged 12 years or older.
